ABSTRACT
The aim of this procedure guideline is the standardization of I-123 metaiodobenzylguanidine scintigraphy, F-18 fluorodeoxyglucose, F-18 fluoropheniylalanine, Ga-68 DOTA peptide positron emission tomography/computerized tomography imaging protochols in pediatric neuroblastoma patients.
Keywords:
Neuroblastoma, pediatrics, I-123 MIBG scintigraphy, F-18 FDG, F-18 DOPA, Ga-68 Ga-68 DOTA peptide
References
1
Young JL Jr, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, surivival, and mortality for children younger than age 15 years. Cancer 1986;58:598-602.
2
Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-I123-iodobenzylguanidine (I-123 MİBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672-682.
3
Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-688.
4
Leung A, Shapiro B, Hattner R, et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997;38:1352-1357.
5
Liu B, Zhuang H, Servaes S. Comparison of [123I] MIBG and [131I] MIBG for imaging of neuroblastoma and other neural crest tumors. Q J Nucl Med Mol Imaging 2013;57:21-28.
6
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG) Nucl Med Commun 1992;13:513-521.
7
Lassmann M, Treves ST; EANM/SNMMI Paediatric Dosage Harmonization Working Group. Paediatric radiopharmaceutical administration: harmonization of the 2007 EANM paediatric dosage card (version 1.5.2008) and the 2010 North American consensus guidelines. Eur J Nucl Med Mol Imaging 2014;41:1036-1041.
8
Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-810.
9
Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med 2013;54:541-548.
10
Lewington V, Lambert B, Poetschger U, et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting method by an international panel. Eur J Nucl Med Mol Imaging 2017;44:234-241.
11
Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-750.
12
Gelfand MJ, Parisi MT, Treves ST; Pediatric Nuclear Medicine Dose Reduction Workgroup. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med 2011;52:318-322.
13
Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. Radiographics 2009;29:1467-1486.
14
Papathanasiou ND, Gaze MN, Sullivan K, et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med 2011;52:519-525.
15
Kong G, Hofman MS, Murray WK, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol 2016;38:87-96.
16
Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008;49:573-586.
17
Gains JE, Bomanji JB, Fersht NL, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 2011;52:1041-1047.
18
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-516.
